PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 2014EuroIntervention121 citationsOpen Access

Occurrence, fate and consequences of ventricular conduction abnormalities after transcatheter aortic valve implantation

View Full Paper
PHPatrick HouthuizenRBRobert M.A. van der BoonMUMarina Ureña

Structured PICO

Does persistent new left bundle branch block after transcatheter aortic valve implantation increase mortality in patients without pre-existing LBBB?

P
Population
476 patients undergoing transcatheter aortic valve implantation (TAVI) without pre-existing left bundle branch block (LBBB) and/or pacemaker before or after TAVI
I
Intervention
Transcatheter aortic valve implantation (TAVI), specifically comparing Medtronic CoreValve System (MCS) and Edwards SAPIEN valve (ES)
C
Comparator
Patients with no LBBB and temporary LBBB combined (for mortality outcome); Edwards SAPIEN valve (for LBBB incidence comparison)
O
Outcome
Development and persistence of new left bundle branch block (LBBB) and its association with mortalityhard clinical

Persistent new-onset left bundle branch block after TAVI is common, occurs more frequently with the Medtronic CoreValve System, and is associated with significantly increased long-term mortality.

Abstract

AIMS: Transcatheter aortic valve implantation (TAVI) is frequently complicated by new left bundle branch block (LBBB). We investigated the development and persistence of LBBB during follow-up and its clinical consequences. METHODS AND RESULTS: ECGs at baseline, within 24 hours, before discharge and at 12 months after TAVI were assessed in 476 patients without pre-existing LBBB and/or pacemaker before or after TAVI. TAVI-induced new LBBB was categorised based on the timing of the occurrence (within 24 hours acute, after 24 hours but before discharge subacute, and after discharge late), in addition to persistence (transient or persistent). A total of 175 patients (36.8%) developed new LBBB of which 85.7% occurred within 24 hours after TAVI, 12.0% before and 2.3% after hospital discharge, and was persistent in 111 patients (63.4%). Implantation of the Medtronic CoreValve System (MCS) more frequently led to new LBBB than the balloon-expandable Edwards SAPIEN valve (ES) (53.8% versus 21.7%) with less recovery during follow-up (39.0% versus 9.5%). Late new LBBB was only seen in four patients (0.8%). During a median follow-up of 915 (578-1,234) days, persistent LBBB was associated with a significant increase in mortality as compared to no LBBB and temporary LBBB combined (hazard ratio 1.49, 95% confidence interval, 1.10-2.03; p=0.01). CONCLUSIONS: TAVI-induced new LBBB occurs in almost 40% of patients, almost all before hospital discharge. It occurs three times more frequently after MCS than after ES valve implantation and has a twofold lower tendency to resolve during follow-up. Persistent LBBB is associated with a higher mortality.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Houthuizen et al. (2014) studied this question.

synapsesocial.com/papers/6a70ab2b439bab0cabc344b1https://doi.org/10.4244/eijv9i10a194
Ask AI
Helpful
Bookmark
Share
View Full Paper